Lila Sciences is reportedly nearing a Series A funding round exceeding $300 million to advance autonomous scientific discovery using AI, while Goodpath secured $18 million for its chronic condition management platform. Separately, LB Pharma experienced strong demand in a rare disease-focused NASDAQ IPO. These financings highlight sustained investor interest in biotech ventures leveraging AI and precision medicine to innovate therapies and diagnostics.